DICOT — Dicot Pharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK611.90m
- SEK498.48m
- SEK0.03m
Annual income statement for Dicot Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.021 | 0.079 | 0.12 | 0.228 | 0.026 |
| Cost of Revenue | |||||
| Gross Profit | -15.1 | -23.8 | -26.5 | -38.7 | -50.8 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 17.6 | 27.3 | 31.8 | 45.2 | 59.3 |
| Operating Profit | -17.5 | -27.2 | -31.7 | -45 | -59.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -17.5 | -27.2 | -31.8 | -44.2 | -57.7 |
| Net Income After Taxes | -17.5 | -27.2 | -31.8 | -44.2 | -57.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.5 | -27.2 | -31.8 | -44.2 | -57.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.5 | -27.2 | -31.8 | -44.2 | -57.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.451 | -0.384 | -0.194 | -0.061 | -0.053 |
| Dividends per Share |